| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Adimmune Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$28.90 |
| 52 Week High | NT$36.60 |
| 52 Week Low | NT$24.35 |
| Beta | 0.44 |
| 11 Month Change | -0.52% |
| 3 Month Change | 3.58% |
| 1 Year Change | -10.25% |
| 33 Year Change | -43.66% |
| 5 Year Change | 15.14% |
| Change since IPO | -58.71% |
Recent News & Updates
Recent updates
Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues
Aug 13
Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality
Apr 05Is Adimmune (TPE:4142) Using Debt In A Risky Way?
Mar 01Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years
Jan 07Shareholder Returns
| 4142 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 2.5% | -0.07% | 3.1% |
| 1Y | -10.2% | 11.1% | 35.5% |
Return vs Industry: 4142 underperformed the TW Biotechs industry which returned 11.1% over the past year.
Return vs Market: 4142 underperformed the TW Market which returned 35.5% over the past year.
Price Volatility
| 4142 volatility | |
|---|---|
| 4142 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in TW Market | 9.4% |
| 10% least volatile stocks in TW Market | 3.0% |
Stable Share Price: 4142 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4142's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | n/a | Steve Chan | www.adimmune.com.tw |
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.
Adimmune Corporation Fundamentals Summary
| 4142 fundamental statistics | |
|---|---|
| Market cap | NT$12.10b |
| Earnings (TTM) | -NT$607.92m |
| Revenue (TTM) | NT$1.66b |
7.4x
P/S Ratio-20.0x
P/E RatioIs 4142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4142 income statement (TTM) | |
|---|---|
| Revenue | NT$1.66b |
| Cost of Revenue | NT$1.20b |
| Gross Profit | NT$460.89m |
| Other Expenses | NT$1.07b |
| Earnings | -NT$607.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 27.82% |
| Net Profit Margin | -36.70% |
| Debt/Equity Ratio | 39.6% |
How did 4142 perform over the long term?
See historical performance and comparison